APPLICANT'S

INFORMATION DISCLOSURE CITATION

(Substitute Form PTO-1449B)

Attorney Docket: 92114.005US1 | Serial No.: 10/607.623

Filing Date: 06/27/03

Applicant: Haim Dansmberg

Group Art Unit: 1614

NON PATENT LITEDATEDE MOCESAUATE

NON PATENT LITERATURE DOCUMENTS Examine: Cite Include assume of the author (in CAPITAL LETTERS), title of the article (when apparentiate), title				
Initials	No.	of the from (book, magazine, junnal, verial, symposium, catalog, etc.), date, page(s), velame-issue number(s), publisher, cit) and/or country where published.	Translation	
	1.	Van Lout, et al., "In Vivo Role of Phagocytic Synovial Lining Cells in Onset of Experimental Arthritis," Am. J. Pathol., 143:1226-37 (1993).	☐ Yei ☐ No ☐ Abstract 🔯 N	
	2	Rogers, et al., "Monocyte Recruitment and Neoinsumal Hyperplasia in Rabbias," Arteriosclerosis, Thromhosis, and Vascular Biology, 16:1312-18 (1996).	☐ Yes ☐ No ☐ Abstract ☑ No	
	3.	Kunnomo, et al., Abstract, "Experimental Induction of Athero Selerosis in Guinea- Pige Fed a Cholesterol Vitamin D-2-Rich Diet" (1983).	☐ Yes ☐ No ⊠ Absumes ☐ N ≥	
	4.	Gennaco, "Parenteral Preparations," Remington: The Science and Practice of Pharmacy, 20th Ed., Ch. 41, pp. 780-920.	☐ Yes ☐ No ☐ Abstract 図 N: A	
	5.	Flusich, "Bisphosphonates in bone disease," Parthenon Publishing Group Inc., pp. 184-210 (1997).	☐ Yes ☐ No ☐ Abelrasa ☑ ArA	
	€1.	Mak, et al., "Clinical Truis to prevent Restenosis after Percutaneous Coronary Revascularization," The NY Academy of Sciences, pp. 225-77 (1994).	☐ Yes ☐ No ☐ Abstract 図 N/A	
	7.	Leolerc, et al., "Drug prevention of restenosis after angioplasty: an update," Elsevier Science, pp. 722-24 (1995).	☐ Yos ☐ No ☐ Alisansa 図 N/A	
	8.	Lefkovits, et al., "Pharmacological Approaches for the Prevention of Restenosis After Percutaneous Coronary Intervantion," <i>Progress in Cardiovascular Disease</i> , 40(2):141-58 (1997).	☐ Yes ☐ NI- ☐ Abstract ☑ N-A	
	9.	Hamon, et al., "Resienosis after coronary angioplasty," Eur. Heart J., 16:33-48 (1995).	☐ Yes ☐ No ☐ Abrillaci ☑ N A	
	10.	Gottsauner-Wolf, et al. "Influence of local delivery of the protein tyrosine kinasc receptor mibilitor tryphostin-47 on smooth-massele cell prodiferation in a rat carotid balloon-ingury model," <i>In. Heart J.</i> , 19347-56 (1996).	☐ Yes ☐ No ☐ Abarson ☑ NiA	
	11.	Shioi, et al., "B-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells," Arterioscleroxis, Thrombosis and Vascular Biology, 15(1):2203-9 (1985).	☐ Yes ☐ No ☐ Abstract ☒ N/A	
	12.	Bellah, et al., "Idiopathic arterial calcification of infancy: Prenatal and postnatal effects of thorspy in an infant," The Journal of Pediatrics, 121(6):930-3 (1992).	☐ Yes ☐ No ☐ Abstract ☒ N/A	
	13.	Waller, et al., "Coronary Artery and Saphenous Vein Graft Remodeling: A Review of Histologic Findings after Various Interventional Procedure — Part VI," Clin. Cardiol., 20:153-60 (1997).	□ Yes □ No □ Alsanso 図 N/A	
	14.	Anderson, et al. "A review of randomized triels comparing scironary angioplasty and hypass grafting," Curr-Opin-Cardiol., 11(6):583-90 (1996).	☐ Ves ☐ Ro ☐ Absunct 図 WA	
	15.	Moormen, et al., "Percutaneous Transhminal Coronary Angioplasty (PTCA): Long- tern Outcome and Aeromedical Implications," Aviation, Space and Environmental Medicine, 671(10):990-6 (1996).	□ Yas □ No □ Abstract 図 foca	
	16.	Laurent, et al., "The arterial wall: a new plurmacological and therapeutic target," Fundom. Clin. Plurmacol., 10:243-57 (1996).	☐ Yes ☐ Site ☐ Abstract ☒ N°A	
	17.	Schwartz, "The vessel wall reaction in restenosis," Semin, Intervent, Cardiol., 2-83-8 (1997).	☐ Yes ☐ No! ☐ Absirbet ◎ N/A	
i de la companya de l	18.	Allaire, ct al., "Endothelial Cell Injury in Cardiovascular Surgery: The Imimal Hyperplastic Response," Ann. Thurac. Surg., 63(2):582-91 (1997).	☐ Yes ☐ No ☐ ANther ❷ N/A	

Senal No.: 10/607,623

Attorney Docket No.: 92114.005US1 Applicant: Haini Danenberg

19.	Webb, et al., "Inhibition of Bioprosthetic Heart Valve Calcification with Antimodiphesphonate Covadently Bound to Residual Aldehyde Groups," Ann. Therac. Surg., 46:309-16 (1988).	□ Yes □ No □ Absence 図 N.A
20.	Weguer, et al., "Courasting Effects of Ethane-1-Hydroxy-1, 1-Diphosphouano (EHDP) on the Regression of two types of Dietary-Induced Atheroselerosis," **Atheroselerosis**, 27:419-35 (1977).	☐ Yes ☐ No ☐ Abstract Ø AcA
21.	Daoust, et al., "The effect of ethane-1-hydroxy-1, 1-hiphosphomate (EHDP) on occrosis of atherosclerotic lexions," Atherosclerots, 67:41-8 (1987).	☐ Yok ☐ Nini ☐ Abelfract ☒ Kir A
22,	Walsh, et al., "Moiecular strategies to inhibit restenosis; modulation of the vascular myocyte phenotype," Semin. Imervent. Cardiol., 1:173-9 (1996).	☐ Yes ☐ No ☐ Abstract Ø N. A
23.	Herman, et al., "Pharmacological Approaches to the Prevention of Restanosis Following Angioplasty," Drugs, 46(1):18-52 (1993).	☐ Y/s ☐ No ☐ Abstract ② N/A
24.	Rubin, et al., "Cellular and Molecular Mechanisms of Radiation Inhibition of Restructive Part Role of the Macrophage and Platelet-Derived Growth Factor," Int. J. Radiation Oncology Biol. Phys., 40:929-41 (1998).	☐ Yes ☐ No ☐ Absumer ❷ N/A
25.	Makkar, et al., "Prevention of Restenosis by Local Drng Delivery," J. Cardiovasc. Pharmneol. Therapeu., 1(2):177-88 (1996).	☐ Yes ☐ No ☐ Abstract ☑ No A
26.	Arefieva, et al., "Monocyte Integrin Expression and Monocyte-Platelet Complex Formation in Humans with Coronary Restenosis," Clin. Exp. Phurm. Physio., 28:804-8 (2001).	□ Yes □ No □ Abstract 図 N/A
27.	Bohm, et al., "Exogenous Hepatitis B Surface Antigen Particles Processed by Dendritis Cells or Macrophages Prime Murine MHC Class I-Restricted Cytotoxic T Lymphocytes In Vivo." J. Immunol., 155:5313-21 (1995).	☐ Yes ☐ No ☐ Abstract 図 NoA
2.8.	Buiting, et al., "Liposomes as antigen carriers and adjuvants in vivi," Res. Immunol., 143:541-8 (1992).	☐ Yes ☐ No ☐ Abstract ② N/A
29.	Bergh, et al., "Liposome-mediated macrophage depletion: an experimental approach to study the role of testicular macrophages in the rat," J. Endocrinol., 136:407-13 (1993).	☐ Yes ☐ Bio ☐ Abstonet 🐯 N/A
30.	Van Rooijen, et al., "Apoptosis of macrophages induced by liposome-mediated intracellular delivery of electronate and propamidine," <i>J. Immunol. Methods</i> , 193:93-91 (1996).	□ Yo □ No □ Alternor ⊠ N/A
31.	Lecusars, et al., "increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo," Immunol., 90:337-43 (1997).	☐ Yes ☐ No ☐ Abstract ⊠ N/A
32.	Yue, et al., "In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Paroxisome Proliferator-Activated Receptor-y Agonist Rosaglitazone," Circulators, 104:2584-94 (2001).	☐ Yes ☐ No ☐ Abstract ❷ N/A
33.	Bolli, et al., "Evidence That Late Preconditioning Against Myocardial Stanning in Conscious Rabbits Is Triggered by the Generation of Nitric Oxole," Circulation Res., 8:14-52 (1997).	□ Yes □ No □ Abstract ⊠ N/A
34.	Zhao, et al., "Myscardial apoptosis and ischemic preconditioning," Cardiovase. Rev., 55.438-55 (2002).	☐ Yes ☐ No ☐ Abstence 図 No.A
35.	Van Rooijen, et al., "The macrophage as target or obstacle in liposome-based targeting strategies," In: J. Pharmacei., 162:45-50 (1998).	☐ Yes ☐ Set ☐ Absent 図 N-A
36.	Matthews, et al., "Comparison of the response of primary human peripheral blood ninnonuclear phagocytes from different donors to challenge with model pellyethylene particles of known size and dose," <i>Biomaterials</i> , 21:2033-44 (2000).	□ Yok □ No □ Ahenes ⊠ NrA

Serial No.: 10/607,623

Attorney Docket No.: 92114.005US1

Applicant Haim Danesberg

	37.	Fisher, et al., "Aleuthronaic mechanism of action: gernapligeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vino." Cell Biol., 96:133-8 (1999).	☐ Ye. ☐ Na ☐ Absraca ❷ N/A
	38.	Sansoni, et al., "Inhibition of antigen-presenting cell function by alendroxate in vitro," J. Bone Min. Res., 10(11):1719-25 (1995).	☐ Yes ☐ No ② Abstract ☐ NoA
	39.	Lodge-Paieli, "The Agoing of Cardiac Infarcts, and its Influence on Cardiac Ropture," Br. Heart J., pp. 37-42 (1951).	☐ Yes ☐ No ☐ Abstract ※ N/A
•••••	40.	Jalowy, et al., "AT1 receptor blockade in experimental myocardial ischemia/reperfusion," Baste Res. Cardiol., 93(2):85-91 (1998).	☐ Yes ☐ No ☐ Absursos ☒ N; A
	41.	Response filed December 22, 2009 in related parent application 10/871,488 in response to October 29, 2009 Final Office Action.	☐ Yis ☐ No ☐ Abstract ❷ N/A
	42.	Non-Fixal Office Action in related patent application 11/190,787 dated Merch 3, 2010.	☐ Yes ☐ No ☐ Absumet ※ N/A
	43.	Response filed June 1, 2010 in related patent application 11/190,787 in response to March 3, 2010 Non-Final Office Action.	☐ Yes ☐ No ☐ Abisiraci ☒ N/A

Exerciner	Date
Signoture	Considered
EXAMINER:	limital if reference considered, whether or not climbou is in conformance with MPEP 2600.
	Draw line through chains if not in confirmance and not considered.
	Include copy of this form with next recommunication to conficunt